PACTR202404671084461
Recruiting
未知
Antenatal magnesium sulphate for short term neuroprotection among women at risk of preterm delivery at 28 to 36 weeks gestation.
Dr Linda James Audu0 sites90 target enrollmentJuly 19, 2023
ConditionsNervous System Diseases
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Nervous System Diseases
- Sponsor
- Dr Linda James Audu
- Enrollment
- 90
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Pregnant women at risk of preterm delivery between 28 to 36weeks of gestation
- •Preterm prelabour rupture of membranes
- •Preterm labour
- •Planned preterm birth for maternal or fetal indication
Exclusion Criteria
- •Congenital anomaly in the foetus
- •Second stage of labour
- •Maternal hypotension
- •Women who received MgSO4 within the last 12 hrs
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Role of Magnesium suplhate to mother in protecting brain of preterm babiesHealth Condition 1: null- Preterm infantsCTRI/2018/06/014386PGIMS
Active, not recruiting
Phase 2
Magnesium sulfate as an adjuvant therapy in neonatal hypoxianeonatal hypoxiahypoxic ischemic encephalopathy S100-b magnesium sulfate neonatesTCTR20180720002Tanta university hospital60
Active, not recruiting
Phase 1
Does magnesium sulphate prevent cerebral palsy in very preterm born infants?EUCTR2011-000735-80-DKene Drasbek Huusom560
Recruiting
Not Applicable
Magnesium sulphate ( magsalf) for fetal neuroprotection.Health Condition 1: O368- Maternal care for other specifiedfetal problemsCTRI/2019/05/019293King Georges Medical University
Completed
Not Applicable
Magnesium sulphate for the treatment of pre-eclampsia: a trial to evaluate the effects on women and babiesPre-eclampsiaPregnancy and ChildbirthISRCTN86938761Medical Research Council (MRC) (UK)10,141